Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.;Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.

Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.;Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.

T evaluate, in participants confirmed with SARS-CoV-2 infection the efficacy of ARDOXSO™ as an interventional exosome therapy in COVID-19 patients.

T evaluate, in participants confirmed with SARS-CoV-2 infection the efficacy of ARDOXSO™ as an interventional exosome therapy in COVID-19 patients.